MTEMQ
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for th… Read more
MTEMQ (MTEMQ) - Total Liabilities
Latest total liabilities as of June 2024: $19.59 Million USD
Based on the latest financial reports, MTEMQ (MTEMQ) has total liabilities worth $19.59 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MTEMQ - Total Liabilities Trend (2020–2023)
This chart illustrates how MTEMQ's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MTEMQ Competitors by Total Liabilities
The table below lists competitors of MTEMQ ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sun Tzu Corporation
PINK:STZU
|
USA | $1.78 Million |
|
GainClients Inc
PINK:GCLT
|
USA | $6.09 Million |
|
Kiley Group Inc.
PINK:KGRI
|
USA | $133.36K |
|
StarTronix International Inc
OTCGREY:STNX
|
USA | $2.10 Million |
|
SES Solar Inc
PINK:SESI
|
USA | $16.70 Million |
|
Nexis International Industries Inc
PINK:NXSI
|
USA | $11.14 Million |
|
Media Way Corp
PINK:MDAW
|
USA | $2.82 Million |
|
Protek Capital Inc.
PINK:PRPM
|
USA | $486.60K |
Liability Composition Analysis (2020–2023)
This chart breaks down MTEMQ's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MTEMQ's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MTEMQ (2020–2023)
The table below shows the annual total liabilities of MTEMQ from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $31.17 Million | -72.34% |
| 2022-12-31 | $112.68 Million | -11.07% |
| 2021-12-31 | $126.70 Million | +57.32% |
| 2020-12-31 | $80.54 Million | -- |